




PCT/GB2004/004211



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Gorse*
Dated 20 October 2004

BEST AVAILABLE COPY

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



1/77

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1.	Your reference	9.14.81642		
2.	Patent application number (The Patent Office will fill in this part)	0323979.5	1400103 E844275-1 000027 P01/7700 0.00-0323979.5	
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	Creative Peptides Sweden AB PO Box SE-113 85 Stockholm Sweden		
	Patents ADP number (if you know it)	08732273001		
	If the applicant is a corporate body, give country/state of incorporation	Sweden		
4.	Title of the invention	Therapeutic applications for C-peptide		
5.	Name of your agent (if you have one)	Frank B. Dehn & Co.		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL		
	Patents ADP number (if you know it)	166001 ✓		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	No		

81642.622

Therapeutic applications for C-peptide

5 The present invention relates to administration of C-peptide in a once daily dose, for use in the treatment of diabetes and diabetic complications.

10 Insulin-dependent diabetes mellitus (IDDM), generally synonymous with type 1 diabetes, is the classical, life-threatening form of diabetes, the treatment of which was revolutionized by the discovery of insulin in 1922. The prevalence of type 1 diabetes is unfortunately widespread throughout much of the world and hence type 1 diabetes represents a serious condition
15 with a significant drain on health resources.

20 The etiology of type 1 diabetes is multifactorial and not yet entirely clear. However it is characterised by a partial or complete autoimmune destruction of the pancreatic beta cells. In the acute phase of type 1 diabetes insulin deficiency is thus the dominating pathophysiological feature.

25 After starting insulin treatment many patients enjoy good blood glucose control with only small doses of insulin. There is an early phase, the "honeymoon period", which may last a few months to a year and which probably reflects a partial recovery of beta cell function. This is, however, a temporary stage and ultimately, the progressive destruction of the beta cells leads to complete cessation of insulin secretion
30 and increasing requirements for exogenous insulin.

35 While the short term effects of hypoinsulinemia in the acute phase of type 1 diabetes can be well controlled by insulin administration, the long term natural history of type 1 diabetes is darkened by the appearance in many patients of potentially serious complications known as late, or late onset complications. These include the specifically diabetic

problems of nephropathy, retinopathy and neuropathy. These conditions are often referred to as microvascular complications even though microvascular alterations are not the only cause. Atherosclerotic disease of the large
5 arteries, particularly the coronary arteries and the arteries of the lower extremities, may also occur.

Nephropathy develops in approximately 35% of type 1 diabetes patients, particularly in male patients and in those with onset of the disease before the age of 15
10 years. Diabetic nephropathy is characterized by persistent albuminuria secondary to glomerular capillary damage, a progressive reduction of the glomerular filtration rate and eventually, end stage renal failure requiring dialysis treatment or kidney transplantation.

15 The prevalence of diabetic retinopathy is highest among young-onset type 1 diabetes patients and it increases with the duration of the disease. Proliferative retinopathy is generally present in about 25% of the patients after 15 years duration and in over
20 50% after 20 years. The earliest lesion of diabetic retinopathy is a thickening of the capillary basement membrane, followed by capillary dilation and leakage and formation of microaneurysms. Subsequently, occlusion of retinal vessels occurs resulting in hypoperfusion of
25 parts of the retina, oedema, bleeding and formation of new vessels as well as progressive loss of vision.

The diabetes-induced nerve disorder is most often a distal symmetric primarily sensory neuropathy affecting 30-50% of type 1 patients. It is often associated with
30 autonomic dysfunction. Sensory neuropathy may cause loss of sensation, appearance of paraesthesia or numbness or, alternatively, result in unpleasant sensations, sometimes pain, in the legs, feet or hands. The morphological changes of diabetic peripheral
35 neuropathy include distal axonal loss with a reduction of the number of large (myelinated) and small fibers, focal demyelination and regenerating activity. The

function abnormalities include slowing of nerve conduction velocities, reduction of nerve signal amplitudes and rises in sensory modality thresholds. Autonomic neuropathy afflicts approximately 50% of the patients with type 1 diabetes of more than 15 years duration. It may evolve through defects in thermoregulation, impotence and bladder dysfunction followed by cardiovascular reflex abnormalities. Late manifestations may include generalized sweating disorders, postural hypotension, gastrointestinal problems and reduced awareness of hypoglycemia. The latter symptom has grave clinical implications.

A number of theories have been advanced with regard to possible mechanism(s) involved in the pathogenesis of the different diabetic complications but this has not yet been fully elucidated. Metabolic factors may be of importance and it has been shown that good metabolic control is accompanied by significantly reduced incidence of complications of all types. Nevertheless, after 7-10 years of good metabolic control, as many as 15-25% of the patients show signs of beginning nephropathy, 10-25% have symptoms of retinopathy and 15-20% show delayed nerve conduction velocity indicating neuropathy. With longer duration of the disease the incidence of complications increases further. There is thus a significant clinical need for the control and management of these diabetic complications.

Proinsulin C-peptide is a part of the proinsulin molecule which, in turn, is a precursor to insulin formed in the beta cells of the pancreas. For a long time it was believed that C-peptide (known variously as C-peptide or proinsulin C-peptide) had no role other than as a structural component of proinsulin, facilitating correct folding of the insulin part. However, it has in more recent years been recognised that C-peptide has a physiological role as a hormone in its own right (Wahren et al., (2000), Am. J. Physiol.

Endocrinol. Metab, 278, E759-E768). In diabetic patients, it alleviates renal dysfunction, improves blood flow in several tissues, ameliorates nerve functional impairments and is believed to delay or prevent the onset of late complications (Wahren et al., (2000) supra; Johansson J et al. Biochem Biophysical Research Comm. 2002; 295:1035-1040; Wahren et al. in International Textbook of Diabetes, 3rd Edition, editors DeFronzo, Ferrannini, Keen and Zimmet, 2003, Wiley, London). Indeed, C-peptide has been proposed for use in the treatment of diabetes in EP 132769 and in SE460334 for use in combination with insulin in the treatment of diabetes and prevention of diabetic complications.

C-peptide is known to have a relatively short half-life. In humans the half-life is approximately 30 minutes and a dose of C-peptide injected into a rat would be expected to have disappeared entirely from circulation within 2-3 hours. Due to the short half-life of C-peptide, in all prior art disclosures several daily doses (typically 3 or 4) or a continuously administered dose are used to treat diabetes or diabetic complications. For example, Sima et al. (Diabetologia, 44, 889-897, 2001) administered C-peptide in a continuous dose by osmopump to diabetic rats. In one known case Ido et al. (Science, 277, 563-566, 1997) administered C-peptide (at 130 nmol per kilogram of bodyweight) twice daily to rats with streptozotocin-induced diabetes. However, in this study human C-peptide was given to rats in a dose approximately five fold higher than otherwise used. Human C-peptide can be expected to be catabolized more slowly in the rat than the homologous C-peptide, which together with the high dosage may account for the observed effect in this study.

Similarly, insulin, which is derived from the same prohormone (proinsulin) as C-peptide requires administration 3-5 times daily.

The inventors of the present application have now surprisingly found that C-peptide given in a once daily dose can be used to treat type I diabetes and diabetic complications effectively. This is particularly surprising since a once daily administration of C-peptide would be expected to leave an animal without detectable C-peptide levels for at least 18-20 hours per day (approximately 75-80% of the time). Thus a new mechanism of action for C-peptide is suggested as it is not believed that the C-peptide remains in the plasma at levels which are sufficient to explain the beneficial effects. This finding offers significant practical advantages to doctor and patient alike in the treatment of diabetes and diabetic complications.

Thus, in one aspect the present invention provides a use of C-peptide or a functionally equivalent fragment, derivative or variant thereof in the manufacture of a medicament for administration to a patient as a once daily dose for the treatment of type I diabetes and/or diabetic complications. 'Diabetic complications' refer to the complications of type I diabetes. Many of the complications are linked to a reduction in $\text{Na}^+\text{K}^+\text{ATPase}$ activity and therefore in a further embodiment, the invention provides the use of C-peptide or a functionally equivalent fragment, derivative or variant thereof in the manufacture of a medicament for administration to a patient as a once daily dose for use in stimulating $\text{Na}^+\text{K}^+\text{ATPase}$ in a patient and/or for treating or preventing conditions associated with a sub-normal $\text{Na}^+\text{K}^+\text{ATPase}$ activity.

Alternatively viewed, the invention provides the use of C-peptide or a functionally equivalent fragment, derivative or variant thereof in the manufacture of a medicament for the treatment of type I diabetes and/or diabetic complications, characterised in that the medicament is for once daily administration to a patient. Also, the invention provides C-peptide or a

functionally equivalent fragment, derivative or variant thereof for use as a once daily dose in therapy, in particular in the treatment of type I diabetes and/or diabetic complications.

5 The present invention also provides the use of C-peptide or a functionally equivalent fragment, derivative or variant thereof in the manufacture of a medicament for the treatment of type I diabetes and/or diabetic complications by administration once a day.
10 Preferably the invention provides the use of C-peptide or a functionally equivalent fragment, derivative or variant thereof in the manufacture of a medicament in the form of an aqueous solution for the treatment of type I diabetes and/or diabetic complications by
15 administration (of said medicament) once a day.

Reference to a 'once daily dose' or 'once daily administration' means, of course, not only that the medicament itself is only given once per day but that the patient receives no other C-peptide treatment. Such
20 instructions may be made clear by the prescribing physician and/or in literature accompanying the packaged medication. The medicament may be adapted for once daily administration. This does not imply the presence of substances which act as release rate controlling
25 agents, indeed the most preferred formulation of the invention is an uncompromised aqueous solution, but it may be reflected in the amount of active agent present, more than would typically be present in a dose prepared for thrice daily administration for example. Specific
30 doses are described below.

"C-peptide" or "pro-insulin C-peptide" as used herein covers C-peptide isolated from any species. Preferably, "C-peptide" refers to human C-peptide having the amino acid sequence EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ
35 (SEQ ID NO. 1).

The term "fragment" as used herein includes fragments of a C-peptide provided that the fragment

retains the biological or therapeutically beneficial activity of the whole molecule. Preferred fragments comprise residues 15-31 of native C-peptide, more especially residues 20-31. Peptides comprising the pentapeptide EGSLQ (SEQ ID NO. 2) (residues 27-31 of native human C-peptide) are also preferred. The fragment may thus vary in size from e.g. 4 to 30 amino acids or 5 to 20 residues.

Suitable fragments are disclosed in WO 98/13384 the contents of which are incorporated herein by reference. Representative fragments include ELGGGPGAG (SEQ ID NO. 3), EGSLQ (SEQ ID NO. 2), ELGG (SEQ ID NO. 4), ELGGGP (SEQ ID NO. 5), GGPGA (SEQ ID NO. 6) or GSLQ (SEQ ID NO. 7). The fragment may also include an N-terminal fragment of C-peptide, typically having the sequence EAEDLQVGAVEL (SEQ ID NO. 8), or a fragment thereof which comprises 2 acidic amino acid residues, capable of adopting a conformation where said two acidic amino acid residues are spatially separated by a distance of 9-14Å between the α -carbons thereof. Also included are fragments having N and/or C-terminal extensions or flanking sequences. The length of such extended peptides may vary, but typically are not more than 50, 30, 25 or 20 amino acids in length.

Nevertheless, C-peptide itself, especially human C-peptide is particularly preferred. Also peptides very closely based on SEQ ID No. 1, e.g. those incorporating 1-4 additional or deleted amino acids or amino acid substitutions, such substitutions preferably being conservative.

The term "derivative" as used herein refers to C-peptide sequences or fragments thereof, which have modifications as compared to the native sequence.

Such modifications may be one or more amino acid deletions, additions, insertions and/or substitutions. Chemical modification of the peptide structure is not precluded e.g. by glycosylation as long as the structure

of the derivative remains essentially peptide in nature. As mentioned above, modification of an amino acid sequence may be by amino acid substitution, for example an amino acid may be replaced by another which preserves the physicochemical character of the peptide (e.g. A may be replaced by G or vice versa, V by A, L or G; E by D or vice versa; and Q by N). Generally, the substituting amino acid has similar properties e.g. hydrophobicity, hydrophilicity, electronegativity, bulky side chains etc. to the amino acid being replaced. Isomers of the 'native' L-amino acid, e.g. D-amino acids may be incorporated.

Additional variants may include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acids. Longer peptides may comprise multiple copies of one or more of the peptide sequences. C and N-terminal protecting groups may be included.

Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced at a site in the protein. Deletional variants are characterised by the removal of one or more amino acids from the sequence.

"Variants" may include, for example, different allelic variants as they appear in nature, e.g. in other species or due to geographical variation etc.

The variants, derivatives and fragments are functionally equivalent in that they exhibit at least 40%, preferably at least 60%, more preferably at least 80% of the activity of proinsulin C-peptide, particularly human C-peptide. Thus are capable of functioning as proinsulin C-peptide i.e. can substitute for C-peptide itself.

Such activity means any activity exhibited by a native C-peptide, whether a physiological response exhibited in an *in vivo* or *in vitro* test system, or any biological activity or reaction mediated by a native C-

peptide, for example in an enzyme assay or in binding to test tissues or membranes.

Thus, it is known that C-peptide increases the intracellular concentration of calcium. An assay for C-peptide activity can thus be by assaying for changes in intracellular calcium concentrations upon addition or administration of the peptide (e.g. fragment or derivative) in question. Such an assay is described in for example in Ohtomo et al., (1996), supra, Kunt et al., supra; Shafqat et al., supra and in Example 1 below.

Further, C-peptide has been found to induce phosphorylation of the MAP-kinases ERK 1 and 2 of a mouse embryonic fibroblast cell line (Swiss 3T3), and measurement of such phosphorylation and MAPK activation may be used to assess, or assay for C-peptide activity, as described for example by Kitamura et al., supra and in Example 2.

C-peptide also has a well known effect in stimulating $\text{Na}^+\text{K}^+\text{ATPase}$ activity and this also may form the basis of an assay for C-peptide activity, for example as described in WO 98/13384 or in Ohtomo et al., (1996), supra or Ohtomo et al., (1998), supra. This is the preferred test to establish 'C-peptide-like' activity and active peptides will preferably induce $\text{Na}^+\text{K}^+\text{ATPase}$ activity in the sciatic nerve by at least 50% over basal levels.

An assay for C-peptide activity based on endothelial nitric oxide synthase (eNOS) activity is also described in Kunt et al., supra, using bovine aortic cells and a reporter cell assay.

Binding to particular cells may also be used to assess or assay for C-peptide activity, for example to cell membranes from human renal tubular cells, skin fibroblasts and saphenous vein endothelial cells using fluorescence correlation spectroscopy, as described for example in Rigler et al., supra, Henriksson et al.,

supra and Pramanik et al., supra. Finally, affinity tests based on measurements of protein binding may be used as activity tests of C-peptide.

5 The "patient" can be any animal but preferably is a human.

Administration of the single daily dose may be by any suitable method known in the medicinal arts, including oral, parenteral, topical, subcutaneous administration or by inhalation. Preferably
10 administration is by subcutaneous administration. The single dose may be administered at any time during the day. For humans, typically, the dosage used is 3-30 nmol/kg of bodyweight/24 hours of C-peptide. Preferably the dose used is 5-20 nmol/kg of bodyweight/24 hours.
15 Thus a single dose as administered will vary depending on the weight of the patient but may typically be in the region of 1200 to 1800 nmol, e.g. about 1500 nmol.

The dose may or may not be in solution. If the dose is administered in solution, it will be appreciated
20 that the volume of the dose may vary, but will typically be 10 μ l - 1 ml. Preferably the dose will be given in a volume of 900 μ l, 800 μ l, 700 μ l, 600 μ l, 500 μ l, 400 μ l, 300 μ l, 200 μ l, 100 μ l, 50 μ l or 20 μ l.

The C-peptide dose in solution can also comprise a
25 preservative and/or a buffer. For example, the preservative m-cresol can be used. Typical concentrations of preservatives include 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml or 5 mg/ml. Examples of buffers that can be used include sodium phosphate
30 buffer (pH 7.3) or sodium bicarbonate buffer (pH 7.3). It will be appreciated that the C-peptide dose may comprise of one or more of C-peptide, fragments, derivatives or functionally equivalent variants of C-peptide. Hence, the single dose may comprise human C-
35 peptide and the C-peptide fragment EGSLQ and/or the N-terminal C-peptide fragment.

In a further embodiment, the present invention

provides the use of a pharmaceutical composition comprising C-peptide or a functional equivalent fragment, derivative or variant thereof in the manufacture of a medicament for administration to a patient as a once daily dose for the treatment of type I diabetes and/or diabetic complications.

Pharmaceutical compositions for use in the present invention may be formulated according to techniques and procedures well known in the art and widely discussed in the literature and may comprise any of the known carriers, diluents or excipients. The compositions may be in the form of (sterile) aqueous solutions and/or suspensions of the pharmaceutically active ingredients, aerosols, ointments and the like. Formulations which are aqueous solutions are most preferred. Such formulations typically contain the peptide itself, water and one or more buffers which act as stabilisers (e.g. phosphate containing buffers) and optionally one or more preservatives. Such formulations containing, e.g. 1200 to 1800 nmol of the peptide constitute a further aspect of the invention.

Compositions to be used in the invention suitable for parenteral administration may comprise sterile aqueous solutions and/or suspensions of the pharmaceutically active ingredients preferably made isotonic with the blood of the recipient, generally using sodium chloride, glycerin, glucose, mannitol, sorbitol and the like.

Compositions of the invention suitable for oral administration may for example comprise peptides in sterile purified stock powder form preferably covered by an envelope or envelopes (enterocapsules) protecting from degradation of the peptides in the stomach and thereby enabling absorption of these substances from the gingiva or in the small intestines.

The total amount of active ingredient in the composition may vary from 99.99 to 0.01 percent of

weight.

As discussed above, the C-peptide dose and pharmaceutical compositions containing this dose can be used in the manufacture of a medicament to treat Type I diabetes and diabetic complications. Such diabetic complications include retinopathy, nephropathy and neuropathy. The administration of the single C-peptide dose can hence be used to improve nerve cell structure (paranodal swelling, paranodal demyelination, intercalated internodes, Wallerian degeneration, regeneration, sequential demyelination and excessive wrinkling). An improvement in $\text{Na}^+\text{K}^+\text{ATPase}$ activity may also be observed. 'Treatment' includes a measurable improvement in one or more of these complications or in the parameters which define type I diabetes e.g. reduction in urinary albumin excretion, reduction or maintenance of plasma creatinine concentration, maintenance or increase in glomerular filtration rate, or improvement in retinal-vitreous body leakage, aneurysm formation or retinal bleeding. The once-daily therapeutic regimen described herein may, optionally in combination with conventional insulin therapy, be useful in preventing or substantially retarding the development of the late diabetic complications discussed above. Thus there may be a prophylactic element to the 'treatments' discussed above.

In a further aspect the invention provides a therapeutic regimen for the treatment of type I diabetes and/or the complications thereof wherein C-peptide or a functionally equivalent fragment, derivative or variant thereof is administered once daily to a patient.

In another embodiment, the invention provides a method of treating type I diabetes and/or diabetic complications in a patient comprising administering C-peptide or a functionally equivalent variant fragment or derivative thereof in a once daily dose. Methods of treatment corresponding to the various additional uses

discussed above are further aspects of the invention.

The method also covers a method of treatment comprising administering one dose of a pharmaceutical composition of the invention.

5 The invention will now be described in more detail in the following non-limiting Examples and with reference to the drawings in which:

10 Figure 1 is a graph showing changes in motor nerve conduction velocity (MNCV) expressed in m/s in healthy control and diabetic animals receiving C-peptide treatment for 8 weeks with different dosing regimens; diab = diabetic, s.c. = subcutaneous;

15 Figure 2 is a graph showing changes in sensory nerve conduction velocity (SNCV) expressed in m/s in healthy control and diabetic animals receiving C-peptide treatment for 8 weeks with different dosing regimens;

20 Figure 3 is a graph showing $\text{Na}^+\text{K}^+\text{ATPase}$ activity in the sciatic nerve ($\mu\text{mol ADP/mg/h}$) in healthy control and diabetic rats receiving C-peptide treatment for 8 weeks with different dosing regimens; and

25 Figure 4 is a table showing teased fiber assessment of nodal and axonal morphometric changes in healthy controls and diabetic rats receiving C-peptide treatment for 8 weeks with different administration regimens.

EXAMPLES

Example 1

5 Further technical details can be found in Sima et al.,
Diabetologia (2001) 44: 889-897.

10 Prediabetic male BB/Wor rats were used. Ten rats were
used in each group, where the animals were closely age-
matched. They were maintained in metabolic cages with
free access to water and rat chow. Bodyweight, urine
volume and glucosuria were monitored daily to ascertain
onset of diabetes. Immediately after the onset of
15 diabetes, administration of C-peptides was commenced in
either a single dose/24 hours, three doses/24 hours or
as a continuous infusion by osmopump.

The single dose given was 75 nmol/kg and the three doses
given were each 25 nmol/kg. The continuous infusion
20 gave a dose of 75 nmol/kg over a 24 hour period.

Synthetic rat C-peptide II with a purity of more than
98% by HPLC was used (Genosys, Cambridge, UK) dissolved
in saline (12 mg/ml). Control rats were given a dose of
25 saline instead of C-peptide.

The nerve conduction velocity in motor and sensory
nerves and Na⁺K⁺ATPase levels in the rats were measured.
Baseline nerve conduction velocity was measured within
30 24 hours of onset of diabetes. Measurements were taken
in the sciatic-tibial nerves under temperature-controlled
conditions (35°C-37°C) as in Sima et al. J. Clin. Invest.
(1996) 97: 1900-1907.

35 To measure Na⁺K⁺ATPase activity and investigate nerve
cell morphology, animals were anaesthetized with Na-
pentobarbital (50 mg/kg bodyweight i.p.) and both

sciatic nerves were dissected, weighed and snap frozen in liquid nitrogen for measurements of nerve glucose, sorbitol, fructose and $\text{Na}^+\text{K}^+\text{ATPase}$ activity. The right sural nerve was fixed in 7.5% glutar aldehyde in 0.1 mol/l cacodylate buffer at pH 7.40 and post fixed in 1% osmium tetroxide (pH 7.40). The distal sural nerve was used for teased fibre preparations.

Insulin and C-peptide concentrations. Serum insulin and C-peptide concentrations were examined using commercially available RIA kits (Linco Research, St. Charles, Mo., USA).

Biochemical analyses. For nerve glucose, sorbitol and fructose, sciatic nerve samples were homogenized in 2 ml of 5% TCA. Aldonitrile derivatives were formed by adding 0.3 ml hydroxylamine in pyridine-methanol 4:1 (vol:vol). Samples were sonicated for 1 mm and 1 ml of acetic anhydride and 2 ml of 1,2 dichloroethane were added and samples were washed in 1.0 N HCl. Samples were reconstituted in 2-butanone and analysed by gas-liquid chromatography.

For $\text{Na}^+/\text{K}^+\text{-ATPase}$ activity, nerve samples were homogenized in 2 ml of 0.2 mol/l sucrose and 0.02 mol/l TRIS-HCl at pH 7.5. Between 10 and 20 μl of the homogenate was assayed enzymatically for total ATPase in 1 ml of 100 mmol/l NaCl, 10 mmol/l KCl, 2.5 mmol/l MgCl_2 , 1 mmol/l TRIS ATP, 1 mmol/l phosphoenolpyruvate, 30 mmol/l imidazole HQ buffer (pH 7.30), 0.15 mmol/l NADH, 50 pg lactate dehydrogenase and 30 μg pyruvate kinase. To measure ouabain-inhibited ATPase, 20 μl of 25 mmol/l of ouabain was added. $\text{Na}^+/\text{K}^+\text{-ATPase}$ activity was defined as the difference before and after ouabain and was expressed as μmol ADP formed per gram of wet weight per hour.

Morphometric analysis. Semithin (0.5 μm) cross-sections of sural nerves were used for morphometric analysis. The following measurements of myelinated fibres were obtained: total number, axonal and myelin size (μm^2),
5 fibre density (n/mm^2), coefficient of variance (CV) of fibre densities between image frames, fibre occupancy (% of endoneurial area), and axon to myelin ratio.

Teased fibre examinations. A mean of 168 ± 4 myelinated
10 fibres were teased from each sural nerve and scored for specific changes. The temporal sequence and increasing severity are represented by normality, paranodal swelling, paranodal demyelination, excessive myelin wrinkling, intercalated inter-nodes, segmental
15 demyelination, Wallerian degeneration, and regeneration. Changes were expressed as percentages of total fibres.

Statistical analysis. The results are presented as means \pm SE and the significance of differences was
20 calculated by analysis of variance (ANOVA). Group differences were assessed by post hoc analysis using the Student-Newman-Keuls test. Tissue samples for biochemical, morphometric and teased fiber analyses were coded to mask animal identity. A p value of less than
25 0.05 was considered statistically significant.

Results

The results can be seen in Figures 1 to 4. The results show that nerve conduction velocity and $\text{Na}^+\text{K}^+\text{ATPase}$
30 activity is clearly and sufficiently improved in rats given a once daily dose of C-peptide and that the once daily dose is as effective as three daily dose or a continuous infusion.

35 The morphometric data also show improved morphology of cells in rats given a once daily dose of C-peptide compared to diabetic rats.

Claims

1. Use of C-peptide or a functionally equivalent fragment, derivative or variant thereof in the
5 manufacture of a medicament for administration to a patient as a once daily dose for the treatment of type I diabetes and/or diabetic complications.
2. Use according to claim 1 wherein the C-peptide is
10 human C-peptide.
3. Use according to any one of claims 1 to 3 wherein the patient is a human.
- 15 4. Use according to any one of claims 1 to 4 wherein the medicament contains 1200 to 1800 nmol of C-peptide or a fragment, derivative or variant thereof.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.